The global sales of cognitive neuroscience are estimated to be worth USD 38,823.7 million in 2024 and anticipated to reach a value of USD 67,584.5 million by 2034. Sales are projected to rise at a CAGR of 6.6% over the forecast period between 2024 and 2034. The revenue generated by cognitive neuroscience in 2023 was USD 36,420.0 million.
These advances in brain imaging have really represented a revolution in the study of cognitive neuroscience, whereby studies into brain function and structure can be conducted at an unprecedented level of detail. This progress is particularly prominent with regard to the development of sophisticated ways of imaging, including fMRI, PET, and EEG.
These range from technologies that have turned the ways scientists investigate the human brain into deeper insights on mental health conditions, cognitive development, and learning processes to social behaviors.
Neuroscience Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 36,420.0 million |
| Estimated Size, 2024 | USD 38,823.7 million |
| Projected Size, 2034 | USD 67,584.5 million |
| Value-based CAGR (2024 to 2034) | 6.6% |
Equally impressive is the advance represented by the technique of functional MRI, or fMRI. This non-invasive method lets researchers measure activity in the working brain by detecting changes in blood flow. Active regions of the brain use more oxygen, and fMRI detects the resulting changes in oxygen levels and can thereby map which parts of the brain are involved in any particular task or cognitive process.
fMRI has also enhanced the building of brain-computer interfaces and neuroprosthetic devices that may one day help restore communication and movement in people who are paralyzed or have neurological disorders affecting movement.
Technologies such as: Diffuse Optical Tomography (DOT), DOT is a kind of non-invasive imaging that utilizes near-infrared light, monitoring the activity of the brain. With respect to other techniques, DOT supplies high-resolution, three-dimensional pictures of the brain through changes in blood flow and oxygen levels. Applications include the study of cognitive functions and conditions related to stroke; this technique offers much safer and more flexible options compared to fMRI.
7-Tesla MRI (7T MRI): The 7-Tesla MRI is considered an ultra-high-field system. It gives far better resolution images compared with conventional MRI machines, which usually operate at 1.5T or 3T. Detail at this level means that small brain structures, such as layers of the cortex, can be visualized and will help study neurodegenerative diseases, vascular disorders, and detailed brain anatomy.
In conclusion, as these technologies continue to evolve, they will undoubtedly drive further innovations in neuroscience research, clinical applications, and the development of new treatments for brain disorders.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The below table presents the expected CAGR for the global cognitive neuroscience market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly lower growth rate of 7.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.3% (2023 to 2033) |
| H2 | 7.0% (2023 to 2033) |
| H1 | 6.6% (2024 to 2034) |
| H2 | 6.1% (2024 to 2034) |
In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly decline in growth rate of 7.0% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.6% in the first half and increase moderately at 6.1% in the second half. In the first half (H1) the market witnessed a decrease of -70.00 BPS while in the second half (H2), the market witnessed an decrease of -90.00 BPS.
Growing Burden of Psychiatric Disorders is Fueling the Market Growth of Cognitive Neurosciences
In recent times, the burdens of psychiatric disorders have emerged as some of the fastest-prevailing medical condition. Neurologic and mental disorders are regarded by the World Health Organization as leading causes of disability in the world. Major depressive disorder probably affects over 280 million persons in the world, while anxiety disorders afflict over 260 million people.
The NIMH estimates that a fifth of adults in the United States lives with a mental illness. The same has been true with other parts of the world, like Europe and Asia, as many cases of psychiatric disorders arise due to stress, urbanization, and changing lifestyles. This growing prevalence has placed a huge burden on health care and therefore underlined the increasing demand for sophisticated research in cognitive neuroscience that will result in more effective treatments.
Additionally, the European Union, on its part, estimates that around 84 million people were affected by poor mental health in the year 2021, according to the European Commission. Such figures bring out the rising burden of psychiatric disorders throughout the world-sketching the need for immediate action with respect to policy in healthcare and investment in research.
Conclusion: As these technologies continue to evolve, they no doubt will spur further innovation in neuroscience research, into clinical practice, and into the development of new treatments for brain disorders.
The Rising Investment in Brain Research Is a Key Opportunity for The Growth of the Cognitive Neuroscience Market
Recognizing that the research on the brain is very important, governments, research institutions, and private companies have been increasing investment in various initiatives pertaining to the brain. In fact, such investments are sorely needed to further drive innovative activities, improve scientific knowledge, and translate this into clinical applications.
That translation into resources will, however, power the market for cognitive neuroscience by accelerating the pace at which new technologies, therapies, and diagnostics benefit mental health, enhance cognition, and treat neurological disorders.
For example, Neuralink is a neurotechnology company that focuses on the development of BCIs capable of directly connecting one's brain to machines. It was founded by Elon Musk back in 2016 and since has received enormous private investments.
The company is working on implantable devices capable of, at their end, helping people with neurological disorders-paralysis, for instance-control external devices such as computers and robotic limbs using their brain signals. The innovations from Neuralink have caught people's eyes worldwide, since they are mirrored by the growing interest in neurotechnology and cognitive neuroscience.
Along with the explosion of public financing, a growing private investment, especially by pharmaceuticals, venture capital, and new Internet related giants like Google and Facebook is witnessed. The pharmaceutical industry is continuously increasing its investments in neuroscience research for new treatments for psychiatric and neurological disorders.
Integration of Artificial Intelligence Will Propel the Overall Market Growth
The integration of AI and ML further revolutionizes how researchers study and understand brain functions. Cognitive neuroscience, a field concerned with the ability of the human brain to process information, make decisions, and adapt to new environments, leads to the generation of vast volumes of complicated data related to neuroimaging, electrophysiological recordings, and behavioral studies. AI and ML are transforming this analysis of data, enabling deeper and more-subtle insights into the function of the brain and cognition.
Traditionally, cognitive neuroscience has depended upon techniques of imaging the brain, such as fMRI, EEG, and MEG. These methods generate enormous datasets that include time-series measures of activity in the brain. Because of their sheer size and complexity, it is beyond the capability of manual analyses or traditional statistical approaches to unlock the full potential of these rich datasets.
It is from there, however, that AI and ML algorithms perform particularly well, processing large, high-dimensional data to elicit meaningful patterns from intricately complex datasets. Deep learning models have been found quite powerful for identifying subtle patterns of brain activity that may reflect cognitive processes such as learning, memory formation, or decision-making.
Another important ability AI/ML allows, in general, is predictive analytics in cognitive neuroscience, which enables one to predict how changes in brain activity might occur for some stimuli or learning process. For example, cognitive decline prediction by a machine learning model in an aging population or the onset of neurodegenerative disease may be predicted by such algorithms, like Alzheimer's.
While automation of data analysis, improved prediction accuracy, and the application of personalized approaches are only a few of the advantages of using AI/ML within this science, it is no doubt that these new methods will be right at the heart of taking cognitive neuroscience research and clinical applications forward.
The High Costs of Imaging Technologies Represent Significant Restraints in The Cognitive Neuroscience Market
Devices such as functional Magnetic Resonance Imaging (fMRI), Positron Emission Tomography (PET), and Magnetoencephalography (MEG), while crucial for the exploration of brain function, are extremely expensive to acquire, install, and maintain. These financial challenges pose barriers for research institutions, hospitals, and companies, especially those with limited resources, curbing the potential growth of the cognitive neuroscience sector.
These financial constraints extend even to the development and adoption of emergent neurotechnologies, including BCIs and neuroprosthetics. Although these technologies have huge potential in cognitive neuroscience and improve the quality of life for individuals with neurological disorders, their development requires substantial funding in research, clinical trials, and regulatory approval. Such funding is unlikely to be readily available, especially to startups or smaller firms just entering the market.
Most of these BCIs, neuroprosthetics, and advanced technologies require extremely expensive clinical trials, given the fact that for them to reach home environments, they undergo a wide amount of testing in both laboratory and real-life settings.
Due to such high R&D costs and the super high regulatory barriers these technologies go through, the commercialization process is strangled and hence slows down their adoption rate. The pace of innovation in this market is also limited by the fact that small players face difficulties competing against big ones with more means to invest in R&D.
Moreover, health systems in developing countries often lack the economic ability to invest in these advanced technologies. Further research in neuroprosthetics-for example, which would greatly contribute to improving the lives of patients with motor impairments-may well remain unattainable in countries with a relatively less coordinated health care system. This reduces their dissemination to more developed countries, adding to existing global imbalances in health care access.
Principal Consultant
The global cognitive neuroscience industry recorded a CAGR of 5.7% during the historical period between 2019 and 2023. The growth of cognitive neuroscience industry was positive as it reached a value of USD 36,420.0 million in 2023 from USD 27,158.0 million in 2019.
Cognitive neuroscience market emerged from an interaction of psychology, neuroscience, and neuropsychology with the intent of finding the relationships among brain structures and functions with cognition, behavior, and mental processes. Its traced back to the mid-20th century, when brain imaging and neurophysiological techniques began to shed light on how the human brain functions for such cognitive activities as memory, building perception, and decision-making.
With functional MRI (fMRI), many researchers can view activities across brain functioning in real time and receive actual pictures on which specific regions are involved in tasks such as language processing, memory retrieval, and making decisions.
The inclusion of artificial intelligence and machine learning will further revolutionize the field, enabling higher levels of data analysis and predictive modeling. These tools allow researchers to uncover hidden patterns in complex brain data, accelerating the discovery process in cognitive decline, mental health, and neuroplasticity. AI-driven personalized therapies and cognitive training programs will probably become a staple in brain health interventions.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 41.7% in global market. These companies are industry leaders with advanced technological capabilities, extensive research and development efforts, and strong financial resources.
They offer a wide array of neurological preducts that monitor several health metrics-from simple measures complex neurological conditions and disease activity pattern. Prominent companies in tier 1 include Siemens Healthineers, Alpha Omega Inc., and GE Healthcare.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 29.7% market share. The cognitive neuroscience market is contributed to by tier 2 companies that have growing influence in the market. Most of the companies are focused on specific niche areas within the area of artificial intelligence and offer customized solutions for specific monitoring needs related to health.
A significant number of tier 2 companies focus on cost-effective solutions and strategic collaborations that increase their market reach. They invest in developing unique features and enhancing user experience with the sole aim of capturing segments of the market. Prominent companies in tier 2 include Scientifica Ltd. and Biobserve GmbH.
Finally, Tier 3 companies, such as NeuroNexus Technology and Laserglow Technologies. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the cognitive neuroscience sales remains dynamic and competitive.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the cognitive neuroscience market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In Asia Pacific, India is projected to witness a CAGR of 13.7% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| China | 13.0% |
| India | 13.7% |
| USA | 3.3% |
| South Korea | 10.4% |
| Canada | 5.8% |
| Spain | 6.9% |
| Germany | 3.5% |
| France | 5.1% |
China cognitive neuroscience market is poised to exhibit a CAGR of 13.0% between 2024 and 2034. Currently, it holds the highest share in the East Asian market, and the trend is expected to continue during the forecast period.
Chinese research institutions, including Tsinghua University, Peking University, and the Chinese Academy of Sciences, have been playing major roles in cognitive neuroscience. Equipped with neuroimaging technologies of the latest generation, including fMRI, PET, and EEG, these institutions conduct research into brain function and neurological disorders equal to leading institutions in the United States and Europe.
China also invests intensely in neurotechnology; in BCI and AI-driven neuroscience research, several startups and even tech giants like Tencent and Alibaba show interest.
The country's growing pharmaceutical and biotechnology industries also aid in this market position. Presently, Chinese firms are increasingly focusing on treatments pertaining to mental health disorders and neurodegenerative diseases by integrating cognitive neuroscience in the R&D process.
USA holds a significant market share in the cognitive neuroscience, which can be attributed to its advanced healthcare infrastructure, high consumer spending power, and strong focus on health innovation. In addition, huge cases of neurological diseases and emphasis on preventive healthcare further add to the demand. With increasing health awareness among American consumers, more rapidly growing adoption of these technologies has taken place for personal health monitoring and management.
Another significant driver is the serious funding committed to projects involving the brain. Programs like the BRAIN Initiative, initiated by the USA government in 2013, have channeled billions into promoting research on the brain and the development of neurotechnology. There is an increasing collaboration between academic centers, universities, and private enterprise. This has led the research institutions, the universities, and the private sector to join hands and speed up advances in cognitive neuroscience.
A blend of technological leadership and brain care initiatives, driven by a robust healthcare system, firmly establishes the lead of the USA in the cognitive neuroscience market.
India’s Cognitive Neuroscience Market is poised to exhibit a CAGR of 13.7% between 2024 and 2034. Currently, it holds the highest share in the Asia Pacific market, and the trend is expected to continue during the forecast period.
The vast and health-conscious population of India has opened up growth opportunities in the cognitive neuroscience market. The rapid urbanization and rise in disposable incomes are drivers of growth in demand for advanced digital therapeutics in healthcare across the country.
Government initiatives towards infrastructure in the healthcare sector, and towards promoting digital health technologies, further add strength to this market. Programs related to increasing access to healthcare and developing telemedicine have also been creating a better climate for wearable devices. With local manufacturers and tech companies coming into the market and providing cost-effective and innovative solutions that really work for Indian consumers, the prospects are bright.
The section contains information about the leading segments in the industry. By type, the magnetic resonance imaging (MRI)segment holds the highest market share of 33.5% in 2024.
| By Type | Magnetic Resonance Imaging (MRI) |
|---|---|
| Value Share (2024) | 33.5% |
With accurate detail of views of structures and functions of the brain, Magnetic Resonance Imaging has dominated the Cognitive Neuroscience market. Of these, functional MRI has emerged as one of the most important tools for understanding cognitive processes since it allows researchers to monitor brain activity in real time by detecting changes in blood flow associated with neural activity. It has allowed scientists to specify which regions of the brain take part in a specific cognitive task, such as memory, attention, and making decisions; this revolutionizes cognitive neuroscience.
Due to the non-invasive nature combined with high spatial resolution, MRI lends itself particularly to both research and clinical purposes. It has been widely used in neurological and psychiatric conditions such as Alzheimer's disease, schizophrenia, and depression, helping to map specific cognitive deficits onto regionally specific alterations in brain morphology.
Besides, technological advances in MRI gave an even greater lead over other techniques by developing techniques allowing researchers to visualize connectivity in the brain and integrity of white matter tracts, such as DTI.
| By Application | Brain Imaging |
|---|---|
| Value Share (2024) | 34.1% |
Diabetes segment has dominated the indication segment do to is high prevalence, thereby acquiring the significant share of 34.1%. Navigation within brain imaging has become the most dominant application in the Cognitive Neuroscience market, as it plays an active role in understanding the sensitive modus operandi of the brain.
Techniques such as functional magnetic resonance imaging, positron emission tomography, electroencephalography, and magnetoencephalography have gained increasing interest for mapping activity and connectivity within the brain.
Among the major factors that ascertain the leading position of brain imaging in this market are its non-invasive nature and capability to provide highly detailed, real-time data on neural activity. This is, however, especially crucial in cognitive neuroscience-the dynamic functioning of the brain holds the key for diagnosis and treatment of neurological and psychiatric disorders like Alzheimer's disease, Parkinson's disease, schizophrenia, and ADHD.
Moreover, imaging techniques allow researchers to follow up the path of a disease and the efficacy of interventions, hence making imaging techniques indispensable both in research and clinics.
The market players are imperatively employing strategic ways to compete and capture business shares, increasing product differentiation through innovation in product features, strategic collaboration with healthcare providers for product distribution, and looking for strategic partners who can support them in widening their product portfolios for global market reach.
Recent Industry Developments in Cognitive Neuroscience Market
In terms of type, the industry is divided into magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), positron emission tomography (PET), magnetoencephalography (MEG), encephalography (EEC), near infrared spectroscopy (NIRS) and single photon emission computed tomography (SPECT).
In terms of application, the industry is segregated into brain imaging, neurological research, neurological disorders and psychiatry.
In the terms of end user, the market is segmented into pharmaceutical companies, clinical & research laboratories, academic research institutes, hospitals & pathology laboratories and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global cognitive neuroscience market is projected to witness CAGR of 6.6% between 2024 and 2034.
The global cognitive neuroscience industry stood at USD 36,420.0 million in 2023.
The global cognitive neuroscience market is anticipated to reach USD 67,584.5 million by 2034 end.
India is set to record the highest CAGR of 13.7% in the assessment period.
The key players operating in the global cognitive neuroscience market include Siemens Healthineers, Scientifica Ltd., Alpha Omega Inc., GE Healthcare, Biobserve GmbH, NeuroNexus Technology, Laserglow Technologies and Kendall Research Systems LLC.
Explore Healthcare Insights
View Reports
Cognitive Neuroscience Market
